Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas

Histopathology

Volumn 29, Issue 6, 1996, Pages 497-505

  Saitoh, K ^a   Takahashi, H ^b   Yamamoto, M ^a   Kishi, H ^a   Parsons, P G ^c  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Malignant melanoma; Melanocytic naevus; Metastasis suppressor gene; nm23

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUPPRESSOR GENE; TUMOR GROWTH;

ADULT; AGED; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM METASTASIS; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030476029     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-537.x     Document Type: Article

References (38)

1. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA et al. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 1988; 80; 200-204.
2. Rosengard AM, Krutzsch HC, Shearn A, Biggs JR, Barker E, Margulies IMK et al. Reduced nm23/awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989; 342; 177-180.
3. Backer JM, Mendora CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy RI Jr et al. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes nm23-1 and nm23-2. Oncogene 1993; 8; 497-502.
4. Stahl JA, Leone A, Rosengard AM, Porter L, Richterking C, Steeg PS. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991; 51; 445-449.
5. Gilles AM, Presecan E, Vonica A, Lascu I. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J. Biol. Chem. 1991; 266; 8784-8789.
6. Agarwal RP, Robinson B, Parks REJ. Nucleoside diphosphate kinase from human erythrocytes. Meth. Enzymol. 1978; 51; 376-386.
7. Parks REJ, Agarwal RP. Nucleoside diphosphokinases. In Boyer PD ed. The Enzymes. New York: Academic Press. 1973; 8; 307-334.
8. Leone A, Flatow U, King CR, Sandeen MA, Margulies IMK, Liotta LA et al. Reduced incidence, metastatic potential, and cytokine resposiveness of NM23 transfected melanoma cells. Cell 1991; 65; 25-35.
9. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993; 8; 2325-2333.
10. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989; 49; 5185-5190.
11. Ayhan A, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Reduced expression of nm23 protein is associated with advanced tumor stage and distant metastases in human colorectal carcinomas. Virchows Arch. B Cell Pathol. 1993; 65; 213-218.
12. Kodera Y, Isobe K, Yamauchi M, Kondoh K, Kimura N, Akiyama S et al. Expression of nm23 H-1 RNA levels in human gastric cancer tissues. A negative correlation with nodal metastasis. Cancer 1994; 73; 259-265.
13. Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992; 52; 6088-6091.
14. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J. Natl. Cancer Inst. 1992; 84; 1349-1354.
15. Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y et al. Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J. Cancer Res. 1993; 84; 1050-1054.
16. Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y et al. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin. Exp. Metastasis 1993; 11; 151-158.
17. Arai T, Watanabe M, Onodera M, Yamashita T, Masunaga A, Itoyama S et al. Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid. Am. J. Pathol. 1993; 142; 1938-1944.
18. Sastre-Garan X, Lacombe ML, Jouve M, Veron M, Magdelenat H. Nucleoside diphosphate kinase/NM23 expression in breast cancer: lack of correlation with lymph-node metastasis. Int. J. Cancer 1992; 50; 533-538.
19. Zou M, Shi Y, Al SS, Farid NR. High levels of Nm23 gene expression in advanced stage of thyroid carcinomas. Br. J. Cancer 1993; 68; 385-388.
20. Haut M, Steeg PS, Willson JK, Markowitz SD. Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential. J. Natl. Cancer Inst. 1991; 83; 712-716.
21. Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R et al. Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value. Br. J. Cancer 1992; 66; 533-536.
22. Engel M, Theisinger B, Seib T, Seitz G, Huwer H, Zang KD et al. High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int. J. Cancer 1993; 55; 375-379.
23. Saitoh K, Takahashi H, Sawada N, Parsons PG. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J. Pathol. (London) 1994; 174; 191-199.
24. Aryee DNT, Strobel T, Kos K, Salzer-Kuntschik M, Zoubek A, Veron M et al. High nm23-H1/NDPK-A expression in Ewing tumours: Paradoxical immunohistochemical reactivity and lack of prognostic significance. Int. J. Cancer 1995; 64; 104-111.
25. Pope JH, Morison L, Moss DJ, Parsons PG, Mary R. Human malignant melanoma cell lines. Pathol. 1979; 11; 1910-1915.
26. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 1979; 76; 4350-4354.
27. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WHJr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46; 1787-1794.
28. Yamamoto M, Takahashi H. Immunohistochemical detection of the p53 protein in tumours of melanocytic origin. Virchows Arch. A Pathol. Anat. 1993; 422; 127-132.
29. Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch. Dermatol. Res. 1995; 287; 146-151.
30. Sawan A, Lascu I, Veron M et al. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J. Pathol. 1994; 172; 27-34.
31. Mandai M, Konishi I, Koshiyama M et al. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995; 75; 2523-2529.
32. Hailat N, Kein DR, Mehem RF, Zhu X, Eckerskorn CF, brodeur GM et al. High levels of p. 19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J. Clin. Invest. 1991; 88; 341-345.
33. Xerri L, Grob JJ, Battyani Z, Gouvernet J, Hassoun Bonerandi JJ. NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br. J. Cancer 1994; 70; 1224-1228.
34. Caligo MA, Grammatico, Cipollini G, Varesco L, Porto D, Bevilacqua G. A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Res. 1994; 4; 179-184.
35. Takahashi H, Parsons PG. In vitro phenotypic alteration of human malignant melanoma cells induced by differentiating agents: Heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression. Pigm. Cell Res. 1990; 3; 223-232.
36. Takahashi H, Saitoh K. Phenotypic modifier hexamethylene bisacetamide (HMBA) induces various phenotypic alterations in human melanoma cells. Jpn. J. Dermatol. 1994; 104; 839-845. (in Japanese).
37. Thomlinson IPM, Gammack AJ, Stickland JE, Mann GJ, MacKie RM, Kefford RF et al. Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers. Genes Chromosomes & Cancer 1993; 7; 169-172.
38. Zeng ZS, Hsu S, Zhang ZF, Cohn AM, Enker WE, Thrnbull AA et al. High level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases. Br. J. Cancer 1994; 70; 1025-1030.